227 related articles for article (PubMed ID: 15975084)
1. Involvement of advanced glycation end-products (AGEs) in Alzheimer's disease.
Takeuchi M; Kikuchi S; Sasaki N; Suzuki T; Watai T; Iwaki M; Bucala R; Yamagishi S
Curr Alzheimer Res; 2004 Feb; 1(1):39-46. PubMed ID: 15975084
[TBL] [Abstract][Full Text] [Related]
2. Possible involvement of advanced glycation end-products (AGEs) in the pathogenesis of Alzheimer's disease.
Takeuchi M; Yamagishi S
Curr Pharm Des; 2008; 14(10):973-8. PubMed ID: 18473848
[TBL] [Abstract][Full Text] [Related]
3. Alternative routes for the formation of glyceraldehyde-derived AGEs (TAGE) in vivo.
Takeuchi M; Yamagishi S
Med Hypotheses; 2004; 63(3):453-5. PubMed ID: 15288367
[TBL] [Abstract][Full Text] [Related]
4. Toxic advanced glycation end products (TAGE) theory in Alzheimer's disease.
Sato T; Shimogaito N; Wu X; Kikuchi S; Yamagishi S; Takeuchi M
Am J Alzheimers Dis Other Demen; 2006; 21(3):197-208. PubMed ID: 16869341
[TBL] [Abstract][Full Text] [Related]
5. TAGE (toxic AGEs) hypothesis in various chronic diseases.
Takeuchi M; Yamagishi S
Med Hypotheses; 2004; 63(3):449-52. PubMed ID: 15288366
[TBL] [Abstract][Full Text] [Related]
6. Glycation--a sweet tempter for neuronal death.
Kikuchi S; Shinpo K; Takeuchi M; Yamagishi S; Makita Z; Sasaki N; Tashiro K
Brain Res Brain Res Rev; 2003 Mar; 41(2-3):306-23. PubMed ID: 12663085
[TBL] [Abstract][Full Text] [Related]
7. Neurotoxicity of advanced glycation end-products for cultured cortical neurons.
Takeuchi M; Bucala R; Suzuki T; Ohkubo T; Yamazaki M; Koike T; Kameda Y; Makita Z
J Neuropathol Exp Neurol; 2000 Dec; 59(12):1094-105. PubMed ID: 11138929
[TBL] [Abstract][Full Text] [Related]
8. Alternative routes for the formation of immunochemically distinct advanced glycation end-products in vivo.
Takeuchi M; Makita Z
Curr Mol Med; 2001 Jul; 1(3):305-15. PubMed ID: 11899079
[TBL] [Abstract][Full Text] [Related]
9. proBDNF is modified by advanced glycation end products in Alzheimer's disease and causes neuronal apoptosis by inducing p75 neurotrophin receptor processing.
Fleitas C; Piñol-Ripoll G; Marfull P; Rocandio D; Ferrer I; Rampon C; Egea J; Espinet C
Mol Brain; 2018 Nov; 11(1):68. PubMed ID: 30428894
[TBL] [Abstract][Full Text] [Related]
10. Glyceraldehyde-derived advanced glycation end products in Alzheimer's disease.
Choei H; Sasaki N; Takeuchi M; Yoshida T; Ukai W; Yamagishi S; Kikuchi S; Saito T
Acta Neuropathol; 2004 Sep; 108(3):189-93. PubMed ID: 15221334
[TBL] [Abstract][Full Text] [Related]
11. Serum or cerebrospinal fluid levels of glyceraldehyde-derived advanced glycation end products (AGEs) may be a promising biomarker for early detection of Alzheimer's disease.
Yamagishi S; Nakamura K; Inoue H; Kikuchi S; Takeuchi M
Med Hypotheses; 2005; 64(6):1205-7. PubMed ID: 15823718
[TBL] [Abstract][Full Text] [Related]
12. Involvement of toxic AGEs (TAGE) in the pathogenesis of diabetic vascular complications and Alzheimer's disease.
Takeuchi M; Yamagishi S
J Alzheimers Dis; 2009; 16(4):845-58. PubMed ID: 19387117
[TBL] [Abstract][Full Text] [Related]
13. Neurotoxicity of acetaldehyde-derived advanced glycation end products for cultured cortical neurons.
Takeuchi M; Watai T; Sasaki N; Choei H; Iwaki M; Ashizawa T; Inagaki Y; Yamagishi S; Kikuchi S; Riederer P; Saito T; Bucala R; Kameda Y
J Neuropathol Exp Neurol; 2003 May; 62(5):486-96. PubMed ID: 12769188
[TBL] [Abstract][Full Text] [Related]
14. The Effect of Glyceraldehyde-Derived Advanced Glycation End Products on β-Tubulin-Inhibited Neurite Outgrowth in SH-SY5Y Human Neuroblastoma Cells.
Nasu R; Furukawa A; Suzuki K; Takeuchi M; Koriyama Y
Nutrients; 2020 Sep; 12(10):. PubMed ID: 32992566
[TBL] [Abstract][Full Text] [Related]
15. Advanced glycation endproducts are associated with Hirano bodies in Alzheimer's disease.
Münch G; Cunningham AM; Riederer P; Braak E
Brain Res; 1998 Jun; 796(1-2):307-10. PubMed ID: 9689484
[TBL] [Abstract][Full Text] [Related]
16. Advanced glycation end products in Alzheimer's disease and other neurodegenerative diseases.
Sasaki N; Fukatsu R; Tsuzuki K; Hayashi Y; Yoshida T; Fujii N; Koike T; Wakayama I; Yanagihara R; Garruto R; Amano N; Makita Z
Am J Pathol; 1998 Oct; 153(4):1149-55. PubMed ID: 9777946
[TBL] [Abstract][Full Text] [Related]
17. An immunochemical study on tau glycation in paired helical filaments.
Ko LW; Ko EC; Nacharaju P; Liu WK; Chang E; Kenessey A; Yen SH
Brain Res; 1999 Jun; 830(2):301-13. PubMed ID: 10366687
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic utility of serum or cerebrospinal fluid levels of toxic advanced glycation end-products (TAGE) in early detection of Alzheimer's disease.
Takeuchi M; Sato T; Takino J; Kobayashi Y; Furuno S; Kikuchi S; Yamagishi S
Med Hypotheses; 2007; 69(6):1358-66. PubMed ID: 17888585
[TBL] [Abstract][Full Text] [Related]
19. Advanced glycation endproducts co-localize with inducible nitric oxide synthase in Alzheimer's disease.
Wong A; Lüth HJ; Deuther-Conrad W; Dukic-Stefanovic S; Gasic-Milenkovic J; Arendt T; Münch G
Brain Res; 2001 Nov; 920(1-2):32-40. PubMed ID: 11716809
[TBL] [Abstract][Full Text] [Related]
20. Advanced glycation endproducts in ageing and Alzheimer's disease.
Münch G; Thome J; Foley P; Schinzel R; Riederer P
Brain Res Brain Res Rev; 1997 Feb; 23(1-2):134-43. PubMed ID: 9063589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
